Wall Street analyst estimates for Vertex Pharmaceuticals Incorporated (VRTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 48 |
| Hold | 7 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 56 |
| Avg rating (1-5) | 0.84 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-02 | $4.76 | ||
| 2026-08-03 | $4.73 | $4.74 | -0.2% |
| 2026-05-04 | $4.47 | $4.24 | +5.4% |
| 2026-02-12 | $5.03 | $5.11 | -1.6% |
| 2025-11-03 | $4.80 | $4.57 | +5.0% |
| 2025-08-04 | $4.52 | $4.29 | +5.4% |
| 2025-05-05 | $4.06 | $4.25 | -4.5% |
| 2025-02-10 | $3.98 | $4.02 | -1.0% |
Valuation Ratios
| P/E Ratio | 29.38 |
| Price / Book | 6.21 |
| EV / EBITDA | 23.59 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.70B | $2.49B | $3.05B | $4.16B | $6.21B | $7.57B | $8.93B | $9.87B | $11.02B | $12.07B |
| Cost of Revenue | $210.5M | $275.1M | $409.5M | $547.8M | $736.3M | $904.2M | $1.08B | $1.26B | $1.53B | $1.81B |
| Gross Profit | $1.49B | $2.21B | $2.64B | $3.62B | $5.47B | $6.67B | $7.85B | $8.61B | $9.49B | $10.27B |
| Research & Development | $1.05B | $1.32B | $1.42B | $1.75B | $1.83B | $3.05B | $2.66B | $3.16B | $3.63B | $3.75B |
| Selling, General & Admin | $432.8M | $496.1M | $557.6M | $658.5M | $770.5M | $840.1M | $944.7M | $1.14B | $1.46B | $1.75B |
| Operating Expenses | $1.48B | $1.82B | $1.97B | $2.41B | $2.61B | $3.89B | $3.54B | $4.78B | $9.72B | $5.51B |
| Operating Income | $9.9M | $123.2M | $635.1M | $1.20B | $2.86B | $2.78B | $4.31B | $3.83B | -$232.9M | $4.76B |
| EBITDA | $75.5M | $103.3M | $706.8M | $1.56B | $3.28B | $2.92B | $4.44B | $4.61B | $486.3M | $4.86B |
| Interest Expense | $81.4M | $69.3M | $34.1M | $58.5M | $58.2M | $61.5M | $54.8M | $44.1M | $30.6M | $13.3M |
| Pre-tax Income | -$67.4M | -$15.7M | $600.2M | $1.39B | $3.12B | $2.73B | $4.23B | $4.38B | $248.5M | $4.64B |
| Income Tax | $16.7M | -$107.3M | -$1.49B | $218.1M | $405.2M | $388.3M | $910.4M | $760.2M | $784.1M | $690.0M |
| Net Income | -$112.1M | $263.5M | $2.10B | $1.18B | $2.71B | $2.34B | $3.32B | $3.62B | -$535.6M | $3.95B |
| EPS | $-0.46 | $1.06 | $8.25 | $4.58 | $10.44 | $9.09 | $12.97 | $14.05 | $-2.08 | $15.46 |
| EPS (Diluted) | $-0.46 | $1.04 | $8.09 | $4.51 | $10.29 | $9.01 | $12.82 | $13.89 | $-2.08 | $15.32 |
| Shares Outstanding (Diluted) | $244.7M | $253.2M | $259.2M | $260.7M | $263.4M | $259.9M | $259.1M | $260.5M | $257.9M | $258.0M |
Price
| Price | $503.50 |
| Market Cap | $127.8B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARGX · BMY · CVS · GSK · HCA · MCK · MDT
Explore sector: Healthcare · Biotechnology
More sections of VRTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks